Anzeige
Mehr »
Dienstag, 04.11.2025 - Börsentäglich über 12.000 News
SuperBuzz explodiert um 20% nach Mega-Deal mit NASDAQ-Werberiesen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
154 Leser
Artikel bewerten:
(1)

MOBILion Systems to Present Transformative Advances in Proteomics Sensitivity and Throughput at HUPO 2025

PAMAF technology delivers near-complete ion utilization, enabling deeper proteome coverage and improved PTM and proteoform analysis

CHADDS FORD, Pa., Nov. 4, 2025 /PRNewswire/ -- MOBILion Systems, Inc., a leader in separation science, announced participation in the upcoming HUPO World Congress, taking place November 9-13, 2025, in Toronto, Canada. MOBILion's CTO, Daniel DeBord will present findings on Parallel Accumulation Mobility Aligned Fragmentation (PAMAF), a breakthrough technique, unique to MOBILion, that dramatically improves mass spectrometry sensitivity and throughput for proteomics and multi-omics.

MOBILion Systems Inc. is advancing separation science with the commercialization of High-Resolution Ion Mobility Mass Spec (HRIM-MS) based on Structures for Lossless Ion Manipulation (SLIM).

As proteomics research increasingly emphasizes PTMs and proteoforms as critical indicators in drug development and clinical diagnostics, technologies that enhance detection depth and confidence are reshaping how scientists interrogate biological complexity. MOBILion's PAMAF technology enables near-100% ion utilization and delivers industry-leading spectral generation rates exceeding 500Hz. This performance advancement can only be achieved via MOBILion's high-speed HRIM separation and reduces the reliance on the slow and lossy quadrupole filtering.

"In a field where incremental gains are often considered meaningful, PAMAF delivers improvements of 300-2,000% in fragment ion intensity boosting identification rates," said Melissa Sherman, Ph.D., CEO of MOBILion Systems. "These advances will enable researchers to identify thousands more proteins and PTMs from smaller samples, opening new frontiers in proteomics, biomarker discovery, and therapeutic development."

DeBord's presentation will feature data from experiments coupling MOBILion's MOBIE® HRIM module with an existing QTOF platform. The results demonstrate up to 100-fold increases in fragment ion intensity, 3-12× more protein groups identified, and 43-53% higher peptide counts per protein, with even greater improvements at low sample inputs, MOBILion's PAMAF mode of operation will be transformative for single-cell proteomics and quantitative PTM measurements.

"These findings highlight improved ion utilization as a fundamental performance lever in mass spectrometry," said DeBord. "By eliminating quadrupole filtering and aligning fragmentation with ion mobility, PAMAF enables more comprehensive, unbiased analysis across complex biological samples, bringing us closer to complete proteome and proteoform coverage."

About MOBILion Systems, Inc.
MOBILion Systems develops high-performance analytical instruments that reveal previously unseen molecular detail by integrating Structures for Lossless Ion Manipulation (SLIM) technology with high-resolution mass spectrometry. The company's proprietary High-Resolution Ion Mobility (HRIM) technology improves separation power, sensitivity, and throughput across proteomics, metabolomics, lipidomics, and clinical research applications. MOBILion's mission is to empower scientists to accelerate discovery, enhance precision medicine, and improve human health by revealing the unseen.

Media contact:
Hannah Steele
The Scott Partnership
mobilionsystems@scottpr.com
+44 1477 539 539

Logo - https://mma.prnewswire.com/media/1831641/MOBILion_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/mobilion-systems-to-present-transformative-advances-in-proteomics-sensitivity-and-throughput-at-hupo-2025-302603752.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.